Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1312-1316

  Czaja, Albert J ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BUDESONIDE; PREDNISONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FEMUR; HUMAN; MALE; METABOLISM; MIDDLE AGED; PILOT STUDY; RETREATMENT; SPINE; TREATMENT FAILURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BONE DENSITY; BUDESONIDE; FEMALE; FEMUR; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; RETREATMENT; SPINE; TREATMENT FAILURE; URSODEOXYCHOLIC ACID;

EID: 0034321507     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.0010000001     Document Type: Article

References (27)

1. Thalen A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittelforschung 1979;29:1687-1690.
2. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518.
3. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E. Influence of 16, 17a-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 1982:16:779-786.
4. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm Venerol 1989;69(suppl 151):11-19.
5. Lofberg R, Danielsson A, Salde L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 1993;7:611-616.
6. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L-G, Persson T, Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994:331:836-841.
7. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen 00, Lorenz-Meyer H, Hodgson H, Persson T, Seidegard C. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331: 842-845.
8. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson L-G, Persson T, Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996:110:45-51.
9. Campieri M, Ferguson A, Doe W, Persson T, Nilsson L-G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997;41:209-214.
10. Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, Odes S, Moshkovitz M, Brück R, Eliakim R, Maoz E, Mittmann U, Israeli Budesonide Study Group. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998;115:835-840.
11. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8: 585-590.
12. Schuler A, Mollman HW, Manns M. Treatment of autoimmune hepatitis with budesonide (abstr). Hepatology 1995;22:488A.
13. Johnson PJ, McFarlane IG, Alvarez F, Blanchi FB, Bianchi L, Burroughs A, Chapman RW, Czaja AJ, Desmet V, Edleston ALWF, Gerber MA, Hoofnagle JH, Kakumu S, MacSween RNM, Maddrey WC, Manns MP, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Portmann BC, Reed WD, Schalm SW, Scheuer PJ, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
14. International Autoimmune Hepatitis Group. Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929938.
15. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-523.
16. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987;92:215-219.
17. Homberg J-C, Abuaf N, Bernard 0, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy V-G, Grippon P, Opolon P, Bernuau J, Benhamou J-P, Alagille D. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7-.1333-1339.
18. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85:713-717.
19. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-1049.
20. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995:333:958-963.
21. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993:105:1824-1832.
22. Angulo P, Therneau TM, Jorgenson RA, DeSotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998:29:729-735.
23. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102(suppl 1A):35S-39S.
24. Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;57:49-68.
25. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 1996;80:973-994.
26. Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984;6:331-335.
27. D'Harens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998;12:419-424.